Doxa AB (DOXA) AI Stock Analysis

• Market Cap: kr547.64M
• Dividend Yield: N/A
• Average Volume (3M): 859.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.30
• Revenue Growth: -2.22%
• EPS Growth: -295.24%
• Country: SE
• Employees: 5
• Sector: Consumer Defensive
• Sector Strength: 57
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.03
• Shares Outstanding: 1,285,530,600
• 10 Day Avg. Volume: 580,453
• 30 Day Avg. Volume: 859,834
• PEG Ratio: 0.28
• Price to Book (P/B): 0.61
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -27.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: kr0.50 ▲(16.28%Upside)

Doxa AB's low overall stock score is primarily driven by its poor financial performance and unfavorable valuation metrics. Technical analysis also points to neutral to bearish sentiment. The absence of earnings call data and corporate events leaves the analysis reliant on existing financial and market indicators.

Doxa AB Business Overview & Revenue Model

Company Description

Doxa AB (DOXA) is a Swedish company that operates within the dental healthcare sector. It specializes in the development, manufacturing, and sale of innovative dental materials. The company is known for its proprietary bioceramic technology, which is utilized in products like dental cements and other restorative materials aimed at enhancing dental procedures and outcomes.

How the Company Makes Money

Doxa AB generates revenue primarily through the sale of its dental products to dental professionals and clinics. The company's key revenue streams include direct sales of its bioceramic-based dental materials, as well as distribution agreements with dental supply companies. Its revenue is further supported by strategic partnerships with dental practitioners and organizations that facilitate the adoption and integration of Doxa's products in dental practices. As a company focused on innovation, Doxa AB also invests in research and development to continually enhance its product offerings and maintain competitive pricing, which helps in sustaining its income.

Doxa AB Financial Statement Overview

Summary

Doxa AB is experiencing significant financial challenges with negative margins, declining EBIT, and weak cash flow generation. Rising debt levels and leverage concerns further compound financial risk, overshadowing the strong equity ratio.

Income Statement

Doxa AB's income statement highlights significant challenges, with consistent negative net income and declining EBIT over the years. The company has not been able to maintain profitability, evidenced by negative EBIT and EBITDA margins, especially in the TTM period. Revenue growth is volatile, with recent declines indicating further instability in financial performance.

Balance Sheet

While Doxa AB has a relatively high level of stockholders' equity compared to its total assets, indicating a strong equity ratio, the increasing level of debt over recent periods raises leverage concerns. The debt-to-equity ratio has worsened, suggesting higher financial risk. Stability is mitigated by significant liabilities and declining asset values.

Cash Flow

The cash flow statement reveals persistent negative operating cash flows and free cash flows, indicating cash management issues. The free cash flow growth rate is negative, showing a lack of improvement in cash flow generation. Additionally, the operating cash flow to net income ratio indicates inefficiency in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.50M	15.50M	9.90M	5.20M	10.90M	8.54M
Gross Profit	10.00M	-540.60M	9.90M	-35.60M	7.90M	8.40M
EBITDA	-1.25B	-1.70B	296.00M	-39.80M	77.20M	-12.20M
Net Income	-1.29B	-1.72B	291.90M	-33.00M	76.20M	-13.69M
Balance Sheet
Total Assets	4.78B	8.20B	3.50B	1.79B	878.80M	14.48M
Cash, Cash Equivalents and Short-Term Investments	241.70M	70.60M	111.90M	60.00M	15.10M	4.58M
Total Debt	1.58B	3.63B	9.70M	4.90M	0.00	0.00
Total Liabilities	2.51B	5.89B	280.80M	18.30M	9.00M	5.04M
Stockholders Equity	2.27B	2.31B	3.22B	1.77B	869.80M	9.44M
Cash Flow
Free Cash Flow	-165.90M	-63.60M	-37.80M	-39.40M	-18.60M	-15.66M
Operating Cash Flow	-165.90M	-63.20M	-37.80M	-38.50M	-18.60M	-14.28M
Investing Cash Flow	-88.80M	-834.90M	-205.10M	-267.30M	-392.90M	-1.34M
Financing Cash Flow	416.90M	807.70M	294.70M	350.70M	422.10M	15.53M

Doxa AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.43
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DOXA, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.44, and below the 200-day MA of 0.61, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.07 is Neutral, neither overbought nor oversold. The STOCH value of 62.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:DOXA.

Doxa AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	70 Outperform	kr1.19B	36.69	10.11%	―	2.53%	-44.90%
CRAD.B	70 Outperform	kr1.19B	36.69	10.11%	―	2.53%	-44.90%
Sector *	64 Neutral	kr25.15B	13.88	159.06%	3.76%	8.53%	-14.21%
INTEG.B	54 Neutral	kr432.02M	―	-19.17%	―	-12.50%	-783.92%
SEDANA	52 Neutral	kr1.18B	―	-5.61%	―	13.66%	-139.90%
SEDANA	52 Neutral	kr1.18B	―	-5.61%	―	13.66%	-139.90%
BRAIN	50 Neutral	kr396.30M	―	-33.54%	―	72.05%	33.68%
MNTC	45 Neutral	kr377.14M	―	-17.16%	―	17.75%	18.05%
MNTC	45 Neutral	kr377.14M	―	-17.16%	―	17.75%	18.05%
DOXA	44 Neutral	kr547.64M	―	-48.55%	―	-2.22%	-295.24%